Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Curanex Pharmaceuticals Inc

NASDAQ: CURX · Life Sciences · 2 alerts · CIK 2025942

Share price
$4.64Close, Nov 16
Market cap
$7.27M
Shares outstanding
1.57MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Curanex Pharmaceuticals Inc filings on SEC EDGAR ↗

1:41 PM ET 10-Q
Financial Results

Curanex Pharmaceuticals Q3 2026 Results: Net Loss of $2.82M, Loss Widens

Curanex Pharmaceuticals Inc reported a net loss of $9.26 million for the nine months ended September 30, 2026, a significant increase from the $1.15 million loss in the prior year period, primarily driven by a surge in Research & Development expenses. The company's cash position decreased to $1.58 million from $4.97 million at the start of the year, reflecting ongoing operational burn as it develops botanical drugs for inflammatory diseases.

Key figure
Net loss $2.82M
5:15 PM ET 8-K
Court & Legal Update

Curanex Pharmaceuticals Court & Legal Update

Curanex Pharmaceuticals disclosed two putative securities class action lawsuits filed in the Supreme Court of the State of New York related to its August 2025 IPO. The complaints allege material misstatements and omissions in the IPO offering documents regarding risks of stock-price manipulation and underwriter due diligence deficiencies. The company intends to defend the actions vigorously and has received extensions to respond to the complaints through late 2026.

Counterparty
Daymond Morales and Robert Lovett

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.